Discover the latest insights into the prevalence and patterns of glomerular diseases as we delve into a comprehensive report from a leading third-level medical center.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
[Epidemiology of glomerular disease: report from a third-level center].
Martínez-Abadía et al., Rev Med Inst Mex Seguro Soc 2023
PMID: 38011679
Summary of Renal Biopsy Epidemiology in a Mexican Center
What’s New: This study provides recent epidemiological data on glomerular diseases from a nephrology center in Mexico, highlighting the prevalence of different types of glomerulopathies and the safety of percutaneous renal biopsy.
Importance: The study addresses the lack of comprehensive data on glomerular diseases in Mexico, which is crucial for understanding the local disease patterns and improving patient management.
Contribution to Literature: The study adds to the limited epidemiological information on renal diseases in Mexico, particularly focusing on the prevalence of primary and secondary glomerulopathies and the associated glomerular syndromes.
Results:
– A total of 89 renal biopsy reports were analyzed.
– 66.29% of the patients were female, 32.70% were male, with an average age of 37.6 ± 12.86 years.
– The most common primary glomerulopathy was focal segmental glomerulosclerosis (FSG) at 22.5%, with membranous nephropathy at 7.9%.
– The leading secondary glomerulopathy was lupus nephropathy, accounting for 42.7%.
– Nephrotic syndrome was the most prevalent glomerular syndrome, occurring in 43.85% of cases.
– Post-biopsy complications were rare, with 89% of patients experiencing no complications.
Conclusion: FSG is the predominant primary glomerulopathy, and nephrotic syndrome is the main reason for performing a renal biopsy. The procedure is deemed safe, with a low complication rate, underscoring its diagnostic value in glomerular diseases.